We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Read MoreHide Full Article
Karyopharm Therapeutics (KPTI - Free Report) shares ended the last trading session 6.9% higher at $5.57. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 48.4% loss over the past four weeks.
Earlier this week, the company reported mixed top-line data from the phase III SENTRY study evaluating a 60 mg dose of selinexor in combination with Jakafi (ruxolitinib) for treating frontline myelofibrosis. The study achieved its first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) in patients treated with the selinexor/Jakafi combination, with rapid, deep and sustained responses observed in the combination arm. However, it failed to meet the second co-primary endpoint of absolute total symptom score (Abs-TSS).
Though the stock initially tanked on this news, it recovered thereafter. This might have driven the recent share price rally.
This pharmaceutical company is expected to post quarterly loss of $1.35 per share in its upcoming report, which represents a year-over-year change of +51.3%. Revenues are expected to be $34.6 million, up 15.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Karyopharm Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KPTI going forward to see if this recent jump can turn into more strength down the road.
Karyopharm Therapeutics is part of the Zacks Medical - Drugs industry. Esperion Therapeutics (ESPR - Free Report) , another stock in the same industry, closed the last trading session 3.3% higher at $2.85. ESPR has returned -17.1% in the past month.
Esperion Therapeutics' consensus EPS estimate for the upcoming report has changed -23.8% over the past month to -$0.04. Compared to the company's year-ago EPS, this represents a change of +81%. Esperion Therapeutics currently boasts a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?
Karyopharm Therapeutics (KPTI - Free Report) shares ended the last trading session 6.9% higher at $5.57. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 48.4% loss over the past four weeks.
Earlier this week, the company reported mixed top-line data from the phase III SENTRY study evaluating a 60 mg dose of selinexor in combination with Jakafi (ruxolitinib) for treating frontline myelofibrosis. The study achieved its first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction of 35% or more (SVR35) in patients treated with the selinexor/Jakafi combination, with rapid, deep and sustained responses observed in the combination arm. However, it failed to meet the second co-primary endpoint of absolute total symptom score (Abs-TSS).
Though the stock initially tanked on this news, it recovered thereafter. This might have driven the recent share price rally.
This pharmaceutical company is expected to post quarterly loss of $1.35 per share in its upcoming report, which represents a year-over-year change of +51.3%. Revenues are expected to be $34.6 million, up 15.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Karyopharm Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KPTI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Karyopharm Therapeutics is part of the Zacks Medical - Drugs industry. Esperion Therapeutics (ESPR - Free Report) , another stock in the same industry, closed the last trading session 3.3% higher at $2.85. ESPR has returned -17.1% in the past month.
Esperion Therapeutics' consensus EPS estimate for the upcoming report has changed -23.8% over the past month to -$0.04. Compared to the company's year-ago EPS, this represents a change of +81%. Esperion Therapeutics currently boasts a Zacks Rank of #3 (Hold).